Halozyme Licenses Enhanze to Roche for New Targets
October 30 2018 - 9:02AM
Dow Jones News
By Colin Kellaher
Halozyme Therapeutics Inc. (HALO) on Tuesday said it licensed
its Enhanze drug-delivery technology to Roche Holding AG (ROG.EB)
for exclusive development of a new undisclosed clinical-stage
therapeutic target, with an option for two more targets within four
years.
The San Diego biotechnology company said the deal includes an
upfront fee of $25 million, along with potential milestone payments
of $160 million to $165 million per target.
Halozyme said it will also receive a fee for each of the two
additional new target nominations, as well as mid-single-digit
royalties on sales of commercialized products.
Halozyme, which signed its first licensing deal with Roche in
2006, said it will recognize the initial $25 million payment in the
fourth quarter.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 30, 2018 08:47 ET (12:47 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
